- Home
- ZTR vs GOSS Comparison
ZTR vs GOSS Comparison
Compare ZTR & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- GOSS
- Stock Information
- Founded
- ZTR 1988
- GOSS 2015
- Country
- ZTR Australia
- GOSS United States
- Employees
- ZTR N/A
- GOSS N/A
- Industry
- ZTR Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- GOSS Health Care
- Exchange
- ZTR Nasdaq
- GOSS Nasdaq
- Market Cap
- ZTR 349.4M
- GOSS 347.8M
- IPO Year
- ZTR N/A
- GOSS 2019
- Fundamental
- Price
- ZTR $6.37
- GOSS $2.47
- Analyst Decision
- ZTR
- GOSS Strong Buy
- Analyst Count
- ZTR 0
- GOSS 4
- Target Price
- ZTR N/A
- GOSS $8.50
- AVG Volume (30 Days)
- ZTR 219.4K
- GOSS 3.1M
- Earning Date
- ZTR 01-01-0001
- GOSS 08-05-2025
- Dividend Yield
- ZTR 12.09%
- GOSS N/A
- EPS Growth
- ZTR N/A
- GOSS N/A
- EPS
- ZTR N/A
- GOSS N/A
- Revenue
- ZTR N/A
- GOSS $40,237,000.00
- Revenue This Year
- ZTR N/A
- GOSS N/A
- Revenue Next Year
- ZTR N/A
- GOSS $30.65
- P/E Ratio
- ZTR N/A
- GOSS N/A
- Revenue Growth
- ZTR N/A
- GOSS N/A
- 52 Week Low
- ZTR $4.50
- GOSS $0.66
- 52 Week High
- ZTR $6.60
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- ZTR 64.07
- GOSS 68.08
- Support Level
- ZTR $6.27
- GOSS $2.38
- Resistance Level
- ZTR $6.35
- GOSS $2.65
- Average True Range (ATR)
- ZTR 0.04
- GOSS 0.15
- MACD
- ZTR 0.01
- GOSS 0.03
- Stochastic Oscillator
- ZTR 85.06
- GOSS 76.67
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.